Lixte Biotechnology (LIXT) Stock Price, News & Analysis

Company Overview

Lixte Biotechnology Holdings, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for the treatment of cancer. The company’s research centers on selectively targeting key enzymes and pathways involved in DNA damage response and cell cycle regulation, with the goal of creating novel oncology drugs that improve patient outcomes with manageable safety profiles.

Lixte’s lead programs include selective inhibitors of cell cycle checkpoints and related targets, designed to potentiate the effects of standard-of-care chemotherapies and overcome resistance mechanisms. These candidates are currently advancing through early-phase clinical trials in solid tumors, where Lixte is evaluating safety, tolerability and preliminary measures of anti-tumor activity. Research and development activities are conducted in collaboration with academic institutions and contract research organizations to leverage cutting-edge science and streamline the path to clinic.

Headquartered in the United States, Lixte Biotechnology maintains its R&D operations in California and works with strategic partners to extend its global reach. The company’s leadership team comprises seasoned executives and scientists with extensive experience in oncology drug development, regulatory affairs and commercial strategy. Through disciplined pipeline management and targeted clinical development, Lixte aims to deliver differentiated therapies that address significant unmet needs in cancer care.

Key Stats

• Today's Range: $4.95 to $5.53
• 50-Day Range: $3.29 to $6.01
• 52-Week Range: $0.64 to $6.26
• Volume: 161,390 shs
• Average Volume: 187,406 shs
• Market Capitalization: $24.26 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Lixte Biotechnology Stock Analysis - MarketRank™

Lixte Biotechnology scored higher than 6% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Lixte Biotechnology.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Lixte Biotechnology is -4.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Lixte Biotechnology is -4.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.27% of the float of Lixte Biotechnology has been sold short.

Short Interest Ratio / Days to Cover

Lixte Biotechnology has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Lixte Biotechnology has recently increased by 110.75%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Lixte Biotechnology does not currently pay a dividend.

Dividend Growth

Lixte Biotechnology does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.27% of the float of Lixte Biotechnology has been sold short.

Short Interest Ratio / Days to Cover

Lixte Biotechnology has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Lixte Biotechnology has recently increased by 110.75%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.7 / 5
• News Sentiment: N/A

News Sentiment

Lixte Biotechnology has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Lixte Biotechnology this week, compared to 1 article on an average week.

Search Interest

3 people have searched for LIXT on MarketBeat in the last 30 days.

MarketBeat Follows

2 people have added Lixte Biotechnology to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Lixte Biotechnology insiders have not sold or bought any company stock.

Percentage Held by Insiders

14.80% of the stock of Lixte Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 5.10% of the stock of Lixte Biotechnology is held by institutions.

LIXT Stock Analysis - Frequently Asked Questions

How have LIXT shares performed this year?

Lixte Biotechnology's stock was trading at $2.03 at the beginning of 2025. Since then, LIXT shares have increased by 162.1% and is now trading at $5.32.

How were Lixte Biotechnology's earnings last quarter?

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) posted its quarterly earnings data on Thursday, August, 7th. The company reported ($0.29) earnings per share (EPS) for the quarter.

When did Lixte Biotechnology's stock split?

Lixte Biotechnology's stock reverse split on Monday, June 5th 2023.The 1-10 reverse split was announced on Monday, June 5th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 5th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did Lixte Biotechnology IPO?

Lixte Biotechnology (LIXT) raised $7 million in an IPO on Wednesday, November 25th 2020. The company issued 1,500,000 shares at $4.75 per share. WestPark Capital and WallachBeth Capital served as the underwriters for the IPO.

How do I buy shares of Lixte Biotechnology?

Shares of LIXT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Lixte Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Lixte Biotechnology investors own include Predictive Oncology (POAI), Sangamo Therapeutics (SGMO), Ford Motor (F), Insulet (PODD), Energy Select Sector SPDR Fund (XLE), Zomedica (ZOM) and Abbott Laboratories (ABT).

Company Calendar

• Last Earnings: 8/07/2025
• Today: 10/04/2025
• Next Earnings (Estimated): 11/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:LIXT
• CIK: 1335105
• Web: www.lixte.com
• Phone: (631) 830-7092
• Fax: 631-982-5050
• Employees: 4
• Year Founded: 2006

Profitability

• EPS (Trailing Twelve Months): ($1.29)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$3.59 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -222.90%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.84
• Quick Ratio: 1.84

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.19) per share
• Price / Book: -4.47

Miscellaneous

• Outstanding Shares: 4,560,000
• Free Float: 3,886,000
• Market Cap: $24.26 million
• Optionable: Not Optionable
• Beta: 0.48